-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Due to the rapid increase in new cases, coviral disease (COVID-19) quickly attracted global attention in 2019, with the pathogen identified as SARS-CoV-2.
So far (July 29), according to real-time statistics released by Johns Hopkins University, there have been more than 16.93 million confirmed cases of new pneumonia worldwide, with 660,000 deaths.
these numbers are updated daily and are expected to increase further.
urgently need small animal models that can sum up SARS-CoV-2 infection.
July 31, 2020, Sun Shihui, Zhou Yusen (deceased), Qin Chengfeng and Jiang Shibo of Fudan University published a research paper entitled "Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccineac" published online in Science, which was adapted to the clinical isolation of the aging BALB/c mouse through continuous transmission.
the lineage of adapted mice produced in the 6th generation (called MASCp6) showed increased infection in the lungs of mice and caused interstitial pneumonia and inflammatory reactions in young and elderly mice after nasal inoculation.
deep sequencing reveals a set of adaptive mutations that may be associated with increased toxicity.
specifically, the N501Y mutation is located in the receptor-binding domain (RBD) of the stingprotein.
the model was used to verify the protective efficacy of recombinant RBD vaccine candidates.
, therefore, the mouse adaptation strain and associated challenge models should be valuable in evaluating vaccines and antiviral drugs for SARS-CoV-2.
coronary virus disease (COVID-19) quickly gained global attention in 2019 due to the rapid increase in new cases.
new coronavirus infection is thought to be transmitted from animals and the pathogen has been identified as SARS-CoV-2.
by January 2020, the initial infected patients are suspected to have been infected through human-to-human transmission.
since January 2020, the virus has spread rapidly to large parts of China and other countries.
the rapid increase in new cases, 2019 coronavirus disease (COVID-19) quickly attracted global attention, with the pathogen identified as SARS-CoV-2.
So far (July 29), according to real-time statistics released by Johns Hopkins University, there have been more than 16.93 million confirmed cases of new pneumonia worldwide, with 660,000 deaths.
these numbers are updated daily and are expected to increase further.
SARS-CoV-2 belongs to the Coronavirus genus of the coronary virus family, along with two other closely related highly pathogenic virusSARS-CoV and MERS-CoV.
the positive chain single-stranded RNA genome length of SARS-CoV-2 is 30 kb, covered by the internal nucleoshell protein (N) and an external envelope consisting of membrane (M) and envelope (E) proteins, as well as the sting (S) protein. similar to SARS-CoV
, the S protein of SARS-CoV-2 binds to the receptor angiotensin conversion enzyme 2 (ACE2) that they share through the receptor binding domain (RBD), thus mediating the virus into the host cell.
previously found that THE RBD of SARS-CoV and MERS-CoV contain the main conformational dependence neutralizing and epial, and can trigger effective neutralizing antibodies in immune animals, thus representing a promising target for vaccine development.
urgently need small animal models that can sum up SARS-CoV-2 infection.
because SARS-CoV-2 does not use mice ACE2 as its receptor, wild mice are considered to be less sensitive to SARS-CoV-2. Genetically modified mice that
expression human ACE2 have been developed using different strategies.
these mice have previously been used to study SARS-CoV-2 infection and pathogenesis and to evaluate responses to COVID-19.
here, the mice reported in the study adaptto the production of SARS-CoV-2, which can be effectively replicated in the respiratory tract and cause mesoplasmic pneumonia in mice with strong wild immune ability. In addition, the protective efficacy of newly developed recombinant subunit vaccine candidates was detected using this mouse attack model.
.